Infection susceptibility, poor vaccination efficacy, age-related disease onset, and neoplasms
are linked to innate and adaptive immune dysfunction that accompanies aging (known as …

Chimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment
paradigms for hematological malignancies, with multi-line therapy-refractory patients …

Vaccination affords protection from disease by activating pathogen-specific immune cells
and facilitating the development of persistent immunologic memory toward the vaccine …

The accumulation of acidic metabolic waste products within the tumor microenvironment
inhibits effector functions of tumor-infiltrating lymphocytes (TILs). However, it remains …

Insufficient eradication capacity and dysfunction are common occurrences in T cells that
characterize cancer immunotherapy failure. De novo DNA methylation promotes T cell …

Cancer cells support their growth and proliferation by reprogramming their metabolism in
order to gain access to nutrients. Despite the heterogeneity in genetic mutations that lead to …

Over the last decade remarkable progress has been made in enhancing the efficacy of CAR
T therapies. However, the clinical benefits are still limited, especially in solid tumors. Even in …

CD8+ T cells are the key executioners of the adaptive immune arm, which mediates
antitumor and antiviral immunity. Naïve CD8+ T cells develop in the thymus and are quickly …

Chimeric antigen receptor (CAR) T cell therapy can achieve outstanding response rates in
heavily pretreated patients with hematological malignancies. However, relapses occur and …

Rapid advances in immunotherapy have identified adoptive cell transfer as one of the most
promising approaches for the treatment of cancers. Large numbers of cancer reactive T …